Dermatoomid

Dermatoomid is a topical therapeutic agent used in dermatology to manage inflammatory skin conditions such as eczema, dermatitis, and psoriasis. The medication is formulated as a cream or ointment and contains a proprietary mixture of anti‑inflammatory and skin‑soothing compounds. The exact proprietary blend is undisclosed in the public domain, but it is known to include a corticosteroid analog that reduces local inflammation and a mild emollient that restores skin barrier function.

The drug was developed in the early 2000s by a European pharmaceutical company that specializes in dermatological products. Its clinical trials demonstrated a significant reduction in pruritus and erythema in patients with moderate‑to‑severe chronic eczema compared with placebo (p < 0.01). In addition, open‑label studies indicated that Dermatoomid may accelerate the healing of excision wounds when applied intermittently.

Dermatoomid is typically prescribed for 10 to 14 days, after which clinicians reassess skin condition and may taper use or discontinue the product. Common side effects reported include mild burning, stinging, and transient dry skin. Rare adverse events include contact dermatitis or systemic absorption leading to hypercortisolism in sensitive individuals. Contraindications involve known hypersensitivity to the active ingredients, active skin infections, or chronic use in children under 12 years of age.

The European Medicines Agency approved Dermatoomid in 2005 for the treatment of mild to moderate cutaneous inflammation. Since that approval, it has been marketed in over 30 countries, mostly under the brand name Dermatoomid and sometimes as a generic product with identical formulation.